Pragmatic clinical trial to assess the utility of SLCO1B1, ABCG2, and CYP2C9 preepmtive genotyping and pharmacogenetics training on the incidence of musculoskeletal adverse reactions in patients treated with statins in primary and specialized care.

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506814-31-01

Acronym

Ap-PriME

Enrollment

1000

Registered

2024-02-19

Start date

2024-06-25

Completion date

Unknown

Last updated

2024-02-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular risk which needs primary or secundary prevention with statins

Brief summary

The incidence of musculoskeletal adverse reactions induced during the first 6 months of treatment (measurement at 6 months).

Detailed description

The incidence of musculoskeletal adverse reactions at 12 months or longer follow up.

Interventions

DRUGPRAVASTATIN

DRUGATORVASTATIN

DRUGPITAVASTATIN

DRUGFLUVASTATIN

DRUGROSUVASTATIN

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
The incidence of musculoskeletal adverse reactions induced during the first 6 months of treatment (measurement at 6 months).	—

Secondary

Measure	Time frame
The incidence of musculoskeletal adverse reactions at 12 months or longer follow up.	—

Countries

Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026